Kumar Rashmi sold $67K of MYGN
Kumar Rashmi sold 15,000 shares of MYRIAD GENETICS INC (MYGN) at $4.46 on 2026-06-08 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest fact is the director’s open-market sale of 15,000 shares on June 8 under a pre-arranged 10b5-1 plan; this is typically treated as lower-signal than discretionary selling.
Market read
Insider selling disclosure may cause minor sentiment noise, but the 10b5-1 structure limits interpretive impact.
What to watch
The article provides only the sale size/price and post-transaction holdings; it does not indicate whether there were offsetting buys or broader insider activity around the same period.
Background
This is a SEC Form 4 insider transaction disclosure for Myriad Genetics, reported via SEC EDGAR.
Ticker impact
Director Kumar Rashmi filed an open-market sale of 15,000 MYGN shares for ~$66,843 under a pre-arranged 10b5-1 plan.
Low likelihood of a sustained price move; any reaction is likely muted and short-lived.
The disclosure is a Form 4 insider transaction with a stated pre-arranged 10b5-1 plan, which typically reduces interpretive value versus discretionary selling.
Market effects
No clear sector read-through from a single director 10b5-1 sale.
None indicated.
None indicated.
Counterpoint
Even with 10b5-1, repeated insider selling can coincide with management’s view of near-term risk or valuation; traders may still fade rallies.
Key entities
- issuerMyriad Genetics Inc
Company whose shares were sold by a director under a 10b5-1 plan.
- insiderKumar Rashmi
Director who executed the open-market sale disclosed on Form 4.
